News FocusBiomedicine

Gene Therapy's Web of Corporate Connections

+ See all authors and affiliations

Science  12 May 2000:
Vol. 288, Issue 5468, pp. 954-955
DOI: 10.1126/science.288.5468.954

You are currently viewing the summary.

View Full Text

Summary

Researchers in gene therapy have become extremely sensitive about perceived conflicts between their financial and scientific portfolios, following the death last year of a volunteer in a clinical trial at the University of Pennsylvania's Institute for Human Gene Therapy (see main text). The trial used a technique for inserting genes into cells that was developed and patented by the institute's head, James Wilson. Wilson and Penn itself have a financial stake in a company Wilson founded to develop the technology.